ContractAsset Purchase Agreement • March 14th, 2008 • Intermune Inc • Pharmaceutical preparations • California
[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
ContractDrug Discovery Collaboration Agreement • March 14th, 2008 • Intermune Inc • Pharmaceutical preparations
[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
February 3, 2006 VIA FAX AND FEDERAL EXPRESS David L. Snitman, Ph.D. Chief Operating Officer Array BioPharma, Inc. 3200 Walnut Street Boulder, CO 80301 RE: Amendment No. 6 to the Drug Discovery Collaboration Agreement Dear Dr. Snitman:Drug Discovery Collaboration Agreement • March 14th, 2008 • Intermune Inc • Pharmaceutical preparations
As you know, InterMune, Inc. (“InterMune”) and Array BioPharma Inc. (“Array”) are parties to that certain Drug Discovery Collaboration Agreement dated September 13, 2002, as amended May 8, 2003, January 7, 2004, September 10, 2004, December 7, 2004 and June 30, 2005 (collectively, the “Agreement”). As we have previously discussed with you and/or John Moore, we would like to further amend the Agreement. Accordingly, the parties agree that the Agreement is hereby amended as follows, effective as of January 1, 2006 (“Amendment Effective Date”):
ContractDrug Discovery Collaboration Agreement • March 14th, 2008 • Intermune Inc • Pharmaceutical preparations
[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
DRUG DISCOVERY COLLABORATION AGREEMENTDrug Discovery Collaboration Agreement • March 14th, 2008 • Intermune Inc • Pharmaceutical preparations • Colorado
This DRUG DISCOVERY COLLABORATION AGREEMENT (the “Agreement”), effective as of September 13, 2002 (the “Effective Date”), is made by and between Array BioPharma Inc., a Delaware corporation, having a principal place of business at 3200 Walnut Street, Boulder, Colorado 80301 (“Array”), and InterMune, Inc., a Delaware corporation, having a principal place of business at 3280 Bayshore Boulevard, Brisbane, California 94005 (“InterMune”).
VIA FAX AND FEDERAL EXPRESS December 7, 2004 David L. Snitman, Ph.D. Chief Operating Officer Array BioPharma, Inc. 3200 Walnut Street Boulder, CO 80301 RE: Amendment No. 4 to the Drug Discovery Collaboration Agreement Dear Dr. Snitman:Drug Discovery Collaboration Agreement • March 14th, 2008 • Intermune Inc • Pharmaceutical preparations
As you know, InterMune, Inc. (“InterMune”) and Array BioPharma Inc. (“Array”) are parties to that certain Drug Discovery Collaboration Agreement dated September 13, 2002, as amended May 8, 2003, January 7, 2004 and September 10, 2004 (collectively, the “Agreement”). The parties agree that the Agreement is hereby amended as follows, effective as of the date of this letter (“Amendment Effective Date”):
Valeant Pharmaceuticals North America One Enterprise Aliso Viejo, CA 92656Product Acquisition Agreement • March 14th, 2008 • Intermune Inc • Pharmaceutical preparations
Re: Product Acquisition Agreement (the “Product Acquisition Agreement”) dated as of November 28, 2005 by and between InterMune, Inc. (“Seller”) and Valeant Pharmaceuticals North America (“Buyer”) – Transition Trademark License
ContractDrug Discovery Collaboration Agreement • March 14th, 2008 • Intermune Inc • Pharmaceutical preparations
[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
LICENSE AGREEMENTLicense Agreement • March 14th, 2008 • Intermune Inc • Pharmaceutical preparations • California
THIS LICENSE AGREEMENT is made and entered into as of August 24, 2004 (the “Effective Date”) by and between InterMune, Inc., a Delaware corporation having its principal place of business at 3280 Bayshore Blvd., Brisbane, California 94005 (“Licensee”), and Chiron Corporation, a Delaware corporation having its principal place of business at 4560 Horton Street, Emeryville, California 94608 (“Chiron”).
June 30, 2005Drug Discovery Collaboration Agreement • March 14th, 2008 • Intermune Inc • Pharmaceutical preparations
As you know, InterMune, Inc. (“InterMune”) and Array BioPharma Inc. (“Array”) are parties to that certain Drug Discovery Collaboration Agreement dated September 13, 2002, as amended May 8, 2003, January 7, 2004, September 10, 2004 and December 7, 2004 (collectively, and as further amended pursuant to this letter, the “Agreement”). The parties agree that the Agreement is hereby amended as follows, effective as of the date of this letter (“Amendment Effective Date”):
